Hepatoma‐derived growth factor regulates breast cancer cell invasion by modulating epithelial–mesenchymal transition
- 13 January 2012
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 228 (2) , 158-169
Abstract
Hepatoma‐derived growth factor (HDGF) participates in tumourigenesis but its role in breast cancer is unclear. We set out to elucidate the expression profile and function of HDGF during breast carcinogenesis. Immunoblot and immunohistochemical studies revealed elevated HDGF expression in human breast cancer cell lines and tissues. Nuclear HDGF labelling index was positively correlated with tumour grade, stage and proliferation index, but negatively correlated with survival rate in breast cancer patients. HDGF over‐expression was associated with lymph node metastasis and represented an independent prognostic factor for tumour recurrence. Gene transfer studies were performed to elucidate the influence of cellular HDGF level on the malignant behaviour and epithelial‐mesenchymal transition (EMT) of breast cancer cells. Adenovirus‐mediated HDGF over‐expression stimulated the invasiveness and colony formation of MCF‐7 cells. Moreover, HDGF over‐expression promoted breast cancer cell EMT by E‐cadherin down‐regulation and vimentin up‐regulation. Conversely, HDGF knockdown by RNA interference in MDA‐MB‐231 cells attenuated the malignant behaviour and elicited EMT reversal by enhancing E‐cadherin expression while depleting vimentin expression. Because HDGF is a secreted protein, we evaluated the cellular function of recombinant HDGF and found that exogenously supplied HDGF enhanced the invasiveness of breast cancer cells by down‐regulating E‐cadherin and up‐regulating vimentin at transcriptional and translational levels. In contrast, blockade of HDGF secretion with an HDGF antibody inhibited the malignant behaviours and EMT. Finally, exogenous HDGF partially reversed benzyl isothiocyanate (BITC)‐induced EMT suppression. HDGF over‐expression may exert a prognostic role for tumour metastasis and recurrence in breast cancer by modulating EMT. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 31 references indexed in Scilit:
- Benzyl Isothiocyanate Inhibits Epithelial-Mesenchymal Transition in Cultured and Xenografted Human Breast Cancer CellsCancer Prevention Research, 2011
- Transforming growth factor-β-induced epithelial–mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progressionOncogene, 2010
- Ki67 in breast cancer: prognostic and predictive potentialThe Lancet Oncology, 2010
- Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancerMolecular Cancer Therapeutics, 2009
- Hepatoma-derived Growth Factor Represses SET and MYND Domain Containing 1 Gene Expression through Interaction with C-terminal Binding ProteinJournal of Molecular Biology, 2009
- The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cellsExperimental Cell Research, 2008
- Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like PhenotypeCancer Research, 2008
- Hepatoma‐derived growth factor is a novel prognostic factor for gastrointestinal stromal tumorsInternational Journal of Cancer, 2007
- Expression of hepatoma‐derived growth factor in hepatocellular carcinomaCancer, 2003
- Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular developmentJournal of Clinical Investigation, 2000